论文部分内容阅读
目的:系统评价二甲双胍与复方醋酸环丙孕酮(CPA)联合应用对多囊卵巢综合征(PCOS)患者内分泌及代谢的影响。方法:计算机检索Cochrane Library、Pub Med、EMbase、中国生物医学文献数据库、维普数据库、中国知网数据库,纳入关于二甲双胍与复方CPA联合应用治疗PCOS的对照研究,检索时限均截止至2015年1月。由2位研究者独立按照纳入与排除标准筛选文献、提取资料和评价纳入研究的方法学质量后,采用Rev Man 5.2软件进行Meta分析。结果:共纳入9个对照研究,合计641例患者。Meta分析结果显示:二甲双胍联合复方CPA组LH/FSH(MD=-0.42,95%CI=-0.55~-0.28,P<0.000 01)、睾酮(SMD=-0.42,95%CI=-0.78~-0.07,P=0.02)、空腹血糖(MD=-0.91,95%CI=-1.28~0.54,P<0.000 01)和空腹胰岛素(MD=-0.63,95%CI=1.07~0.43,P=0.005)等方面均优于单纯复方CPA组。结论:当前证据表明,二甲双胍联合复方CPA对PCOS患者内分泌激素及代谢的改善效果优于单纯复方CPA。
OBJECTIVE: To systematically evaluate the effect of combination of metformin and CPP on the endocrine and metabolism of patients with polycystic ovary syndrome (PCOS). Methods: The Cochrane Library, Pub Med, EMbase, Chinese Biomedical Literature Database, VIP database and CNKI database were searched by computer. The controlled study on the combination of metformin and CPA in the treatment of PCOS was completed. The search time was up to January 2015. Two researchers independently screened the literature for inclusion and exclusion criteria, extracted data, and evaluated the methodological quality of the included studies. Meta-analysis was performed using Rev Man 5.2 software. Results: A total of 9 controlled studies were included, totaling 641 patients. The result of Meta - analysis showed that LH / FSH of metformin combined with CPA group (MD = -0.42, 95% CI = -0.55-0.28, P <0.000 01) and testosterone (SMD = -0.42, 95% CI -0.78 - 0.07, P = 0.02), fasting plasma glucose (MD = -0.91, 95% CI = -1.28-0.54, P <0.000 01) and fasting insulin (MD = -0.63, 95% CI = 1.07-0.43, P = 0.005) Etc. are better than simple compound CPA group. CONCLUSIONS: Current evidence suggests that metformin plus CPA is superior to CPA alone in improving the effects of endocrine hormones and metabolism in patients with PCOS.